Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. Israel New York United States of America Massachusetts

View original content:https://www.prnewswire.co.uk/news-releases/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-validation-of-variation-submission-by-european-medicines-agency-for-pegunigalsidase-alfa-302325605.html